SCHEMBL1016159

SCHEMBL1016159

CC(=O)Nc1ccc(-c2ccc(C)c(N)c2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.63
HTT P42858 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
HDAC1 Q13547 4/20 0.53
TDP1 Q9NUW8 1/20 0.52
HDAC3 O15379 2/20 0.51
HDAC2 Q92769 2/20 0.51
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA9 Q16790 2/20 0.47
BRD4 O60885 1/20 0.47
NR1I2 O75469 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30483162 0.86 TDP1 (0.57) SMN1; SMN2HTTL3MBTL1TDP1MEN1
SCHEMBL2081736 0.86 TDP1 (0.57) SMN1; SMN2HTTL3MBTL1TDP1MEN1
SCHEMBL1016291 0.86 ALDH1A1 (0.57) SMN1; SMN2HDAC1HDAC3HDAC2MEN1
SCHEMBL11593633 0.81 CACNA1B (0.57) SMN1; SMN2HTTL3MBTL1HDAC1TDP1
SCHEMBL3818831 0.80 SMN1; SMN2 (1.00) SMN1; SMN2HTTL3MBTL1TDP1MEN1
SCHEMBL3225408 0.78 SMN1; SMN2 (0.79) SMN1; SMN2HTTL3MBTL1HDAC1TDP1
SCHEMBL9762638 0.78 SMN1; SMN2 (0.86) SMN1; SMN2HTTL3MBTL1TDP1MEN1
SCHEMBL6796771 0.77 ALDH1A1 (0.67) SMN1; SMN2HTTL3MBTL1HDAC1HDAC3
SCHEMBL11244788 0.76 TDP1 (0.87) SMN1; SMN2HTTL3MBTL1TDP1MEN1
SCHEMBL28606238 0.75 SMN1; SMN2 (0.61) SMN1; SMN2HTTL3MBTL1HDAC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415479-B2 Inhibitor of plasminogen activator inhibitor-1 RENASCIENCE CO., LTD. (JP) 2013-04-09 US disclosed
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 RENASCIENCE CO., LTD. (JP) 2011-05-12 US disclosed
EP-2272822-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 Renascience CO., LTD. (JP) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112140-A1 INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 SERPINE1, SERPINB1, SERPINC1 SMN1; SMN2 2290/4885HTT 1349/4885L3MBTL1 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.